CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Ifosfamide +2 moredrug
Likely dose
Ifosfamide 1.2 gm/m2/day for 5 days (pre-radiation, 3 cycles every 21 days) followed by ifosfamide 1.0 gm/m2/day for 5 days (post-radiation)AI-extracted
Key inclusion· 4
  • Histologically confirmed mixed mesodermal tumor (MMT) of the uterus with no visible residual disease after surgery
  • Surgical staging completed with total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node sampling
  • Surgical staging completed 6 weeks ± 7 days prior to enrollment
  • Age 18 years or older
Key exclusion· 5
  • Severe or uncontrolled medical disease including uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, or congestive heart failure
  • Prior chemotherapy or radiotherapy for pelvic malignancy
  • Myelosuppressive chemotherapy within 3 weeks prior to study entry
  • Uterine sarcoma other than mixed mesodermal tumor (MMT)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00231842
NCT00231842Phase 2Completed

A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors

Montefiore Medical Center·interventional·Posted Oct 4, 2005·Updated Jan 23, 2019

In Brief

A Phase 2 clinical trial evaluating Ifosfamide, Radiation Therapy, and 1 other intervention for Uterine Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established. The rationale for the protocol is to "sandwich" pelvic radiation with chemotherapy to decrease distant metastasis. The proposed study will sandwich radiation between the two most active chemotherapeutic agents for MMT identified to date (ifosfamide/cisplatin). By doing so, we attempt to decrease both local and distant recurrence, which may translate into an improved progression free interval and possibly even extend survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 4, 2005
Enrollment StartFeb 1, 2003
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 20.7 years ago

Interventions

Ifosfamidedrug

Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.

Radiation Therapydevice

Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.

Cisplatindrug

dosage is 20 mg/m2/day for 5 days, ever 3 weeks.